{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T08:25:14Z","timestamp":1770884714949,"version":"3.50.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T00:00:00Z","timestamp":1731110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T00:00:00Z","timestamp":1731110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008762","name":"Genome Canada","doi-asserted-by":"publisher","award":["G05CHS"],"award-info":[{"award-number":["G05CHS"]}],"id":[{"id":"10.13039\/100008762","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40258-024-00926-9","type":"journal-article","created":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T10:25:22Z","timestamp":1731147922000},"page":"441-452","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Using Genomic Heterogeneity to Inform Therapeutic Decisions for Metastatic Colorectal Cancer: An Application of the Value of Heterogeneity Framework"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0159-582X","authenticated-orcid":false,"given":"Reka E.","family":"Pataky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8243-8721","authenticated-orcid":false,"given":"Stuart","family":"Peacock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7093-3058","authenticated-orcid":false,"given":"Stirling","family":"Bryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0419-7862","authenticated-orcid":false,"given":"Mohsen","family":"Sadatsafavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8876-0511","authenticated-orcid":false,"given":"Dean A.","family":"Regier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,9]]},"reference":[{"issue":"20","key":"926_CR1","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa071834","volume":"357","author":"DJ Jonker","year":"2007","unstructured":"Jonker DJ, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357(20):2040\u20138.","journal-title":"N Engl J Med"},{"issue":"14","key":"926_CR2","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1200\/JCO.2007.13.1193","volume":"26","author":"AF Sobrero","year":"2008","unstructured":"Sobrero AF, et al. EPIC: phase III Trial of Cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(14):2311\u20139.","journal-title":"J Clin Oncol"},{"issue":"13","key":"926_CR3","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","volume":"25","author":"E Van Cutsem","year":"2007","unstructured":"Van Cutsem E, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25(13):1658\u201364.","journal-title":"J Clin Oncol"},{"issue":"10","key":"926_CR4","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","volume":"26","author":"RG Amado","year":"2008","unstructured":"Amado RG, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(10):1626\u201334.","journal-title":"J Clin Oncol"},{"issue":"1","key":"926_CR5","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1586\/14737167.2015.982100","volume":"15","author":"K Lien","year":"2015","unstructured":"Lien K, et al. The use of EGFR inhibitors in colorectal cancer: is it clinically efficacious and cost-effective? Expert Rev Pharmacoecon Outcomes Res. 2015;15(1):81\u2013100.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"17","key":"926_CR6","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","volume":"359","author":"CS Karapetis","year":"2008","unstructured":"Karapetis CS, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359(17):1757\u201365.","journal-title":"N Engl J Med"},{"key":"926_CR7","unstructured":"BC Cancer Agency, BCCA protocol summary: third line treatment of metastatic colorectal cancer using cetuximab in combination with irinotecan 2009."},{"key":"926_CR8","unstructured":"BC Cancer Agency, BCCA protocol summary for palliative third line treatment of metastatic colorectal cancer using panitumumab 2009."},{"issue":"11","key":"926_CR9","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","volume":"369","author":"J-Y Douillard","year":"2013","unstructured":"Douillard J-Y, et al. Panitumumab\u2013FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369(11):1023\u201334.","journal-title":"N Engl J Med"},{"issue":"7","key":"926_CR10","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1158\/1078-0432.CCR-12-1913","volume":"19","author":"M Peeters","year":"2013","unstructured":"Peeters M, et al. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin Cancer Res. 2013;19(7):1902\u201312.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"926_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/annonc\/mdu378","volume":"26","author":"MJ Sorich","year":"2015","unstructured":"Sorich MJ, et al. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol. 2015;26(1):13\u201321.","journal-title":"Ann Oncol"},{"key":"926_CR12","unstructured":"BC Cancer. New genetic tests become standard of cancer care in BC. 2016 September 7, 2016 July 19, 2020]; Available from: http:\/\/www.bccancer.bc.ca\/about\/news-stories\/news\/2016\/new-genetic-tests-become-standard-of-cancer-care-in-bc."},{"issue":"17","key":"926_CR13","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1093\/jnci\/djp232","volume":"101","author":"N Mittmann","year":"2009","unstructured":"Mittmann N, et al. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO17 trial. J Natl Cancer Inst. 2009;101(17):1182\u201392.","journal-title":"J Natl Cancer Inst"},{"issue":"25","key":"926_CR14","first-page":"1","volume":"10","author":"Medical Advisory Secretariat","year":"2010","unstructured":"Medical Advisory Secretariat. KRAS testing for anti-EGFR therapy in advanced colorectal cancer: an evidence-based and economic analysis. Ont Health Technol Assess Ser. 2010;10(25):1\u201349.","journal-title":"Ont Health Technol Assess Ser"},{"issue":"2","key":"926_CR15","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jval.2012.11.001","volume":"16","author":"M Hoyle","year":"2013","unstructured":"Hoyle M, et al. Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer. Value in Health. 2013;16(2):288\u201396.","journal-title":"Value in Health"},{"issue":"3","key":"926_CR16","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S1470-2045(12)70044-X","volume":"13","author":"F Rinaldi","year":"2012","unstructured":"Rinaldi F, George E, Adler AI. NICE guidance on cetuximab, bevacizumab, and panitumumab for treatment of metastatic colorectal cancer after first-line chemotherapy. Lancet Oncol. 2012;13(3):233\u20134.","journal-title":"Lancet Oncol"},{"issue":"6","key":"926_CR17","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s41669-023-00444-9","volume":"7","author":"RE Pataky","year":"2023","unstructured":"Pataky RE, et al. Real-world cost effectiveness of a policy of KRAS testing to inform cetuximab or panitumumab for third-line therapy of metastatic colorectal cancer in British Columbia, Canada. Pharmacoecon Open. 2023;7(6):997\u20131006.","journal-title":"Pharmacoecon Open"},{"issue":"1","key":"926_CR18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1634\/theoncologist.2014-0252","volume":"20","author":"SM Kircher","year":"2015","unstructured":"Kircher SM, Mohindra N, Nimeiri H. Cost estimates and economic implications of expanded RAS testing in metastatic colorectal cancer. Oncologist. 2015;20(1):14\u20138.","journal-title":"Oncologist"},{"key":"926_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcpo.2024.100496","volume":"41","author":"RE Pataky","year":"2024","unstructured":"Pataky RE, et al. Real-world cost-effectiveness of panel-based genomic testing to inform therapeutic decisions for metastatic colorectal cancer. J Cancer Policy. 2024;41: 100496.","journal-title":"J Cancer Policy"},{"issue":"8","key":"926_CR20","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1177\/0272989X14538705","volume":"34","author":"MA Espinoza","year":"2014","unstructured":"Espinoza MA, et al. The value of heterogeneity for cost-effectiveness subgroup analysis: conceptual framework and application. Med Decis Making. 2014;34(8):951\u201364.","journal-title":"Med Decis Making"},{"issue":"10","key":"926_CR21","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s40273-022-01176-0","volume":"40","author":"RE Pataky","year":"2022","unstructured":"Pataky RE, et al. Tools for the economic evaluation of precision medicine: a scoping review of frameworks for valuing heterogeneity-informed decisions. Pharmacoeconomics. 2022;40(10):931\u201341.","journal-title":"Pharmacoeconomics"},{"issue":"19","key":"926_CR22","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1002\/sim.5753","volume":"32","author":"DF McCaffrey","year":"2013","unstructured":"McCaffrey DF, et al. A tutorial on propensity score estimation for multiple treatments using generalized boosted models. Stat Med. 2013;32(19):3388\u2013414.","journal-title":"Stat Med"},{"issue":"4","key":"926_CR23","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/sim.2580","volume":"26","author":"PC Austin","year":"2007","unstructured":"Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med. 2007;26(4):734\u201353.","journal-title":"Stat Med"},{"issue":"4","key":"926_CR24","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1037\/1082-989X.9.4.403","volume":"9","author":"DF McCaffrey","year":"2004","unstructured":"McCaffrey DF, Ridgeway G, Morral AR. Propensity score estimation with boosted regression for evaluating causal effects in observational studies. Psychol Methods. 2004;9(4):403\u201325.","journal-title":"Psychol Methods"},{"issue":"3","key":"926_CR25","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/sim.3782","volume":"29","author":"BK Lee","year":"2010","unstructured":"Lee BK, Lessler J, Stuart EA. Improving propensity score weighting using machine learning. Stat Med. 2010;29(3):337\u201346.","journal-title":"Stat Med"},{"key":"926_CR26","unstructured":"Burgette L, Griffin BA and McCaffrey D. Propensity scores for multiple treatments: A tutorial for the mnps function in the twang package. 2021; Available from: https:\/\/cran.r-project.org\/web\/packages\/twang\/vignettes\/mnps.pdf."},{"key":"926_CR27","unstructured":"Ridgeway G et al. Toolkit for weighting and analysis of nonequivalent groups: a guide to the twang package. 2021; Available from: https:\/\/cran.r-project.org\/web\/packages\/twang\/index.html."},{"key":"926_CR28","doi-asserted-by":"crossref","unstructured":"Willan AR and Briggs AH. Parameter estimation for censored data. In: Statistical Analysis of Cost\u2010effectiveness Data. 2006. pp. 27\u201342.","DOI":"10.1002\/0470856289.ch3"},{"issue":"3","key":"926_CR29","first-page":"95","volume":"12","author":"CD Oliveira","year":"2017","unstructured":"Oliveira CD, et al. Estimating the cost of cancer care in British Columbia and Ontario: a Canadian inter-provincial comparison. Healthcare Policy. 2017;12(3):95\u2013108.","journal-title":"Healthcare Policy"},{"key":"926_CR30","unstructured":"Canadian Agency for Drugs and Technologies in Health, Guidelines for the economic evaluation of health technologies: Canada. 4th ed. 2017, CADTH: Ottawa, ON."},{"issue":"5","key":"926_CR31","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/hec.678","volume":"11","author":"JS Hoch","year":"2002","unstructured":"Hoch JS, Briggs AH, Willan AR. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econ. 2002;11(5):415\u201330.","journal-title":"Health Econ"},{"issue":"9","key":"926_CR32","doi-asserted-by":"publisher","first-page":"781","DOI":"10.2165\/00019053-200826090-00008","volume":"26","author":"K Claxton","year":"2008","unstructured":"Claxton K. Exploring uncertainty in cost-effectiveness analysis. Pharmacoeconomics. 2008;26(9):781.","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"926_CR33","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s40273-012-0017-2","volume":"31","author":"M Frank","year":"2013","unstructured":"Frank M, Mittendorf T. Influence of pharmacogenomic profiling prior to pharmaceutical treatment in metastatic colorectal cancer on cost effectiveness. Pharmacoeconomics. 2013;31(3):215\u201328.","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"926_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0204496","volume":"13","author":"MK Seo","year":"2018","unstructured":"Seo MK, Cairns J. Do cancer biomarkers make targeted therapies cost-effective? A systematic review in metastatic colorectal cancer. PLoS\u00a0One. 2018;13(9): e0204496.","journal-title":"PLoS\u00a0One"},{"issue":"1","key":"926_CR35","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jval.2019.07.009","volume":"23","author":"B Unim","year":"2020","unstructured":"Unim B, et al. Cost-effectiveness of RAS genetic testing strategies in patients with metastatic colorectal cancer: a systematic review. Value Health. 2020;23(1):114\u201326.","journal-title":"Value Health"},{"issue":"2","key":"926_CR36","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1002\/ijc.26400","volume":"131","author":"A Vijayaraghavan","year":"2012","unstructured":"Vijayaraghavan A, et al. Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany. Int J Cancer. 2012;131(2):438\u201345.","journal-title":"Int J Cancer"},{"key":"926_CR37","doi-asserted-by":"publisher","DOI":"10.3310\/hta17140","author":"M Hoyle","year":"2013","unstructured":"Hoyle M, et al. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-lin. Health Technol Assess. 2013. https:\/\/doi.org\/10.3310\/hta17140.","journal-title":"Health Technol Assess"},{"issue":"19","key":"926_CR38","doi-asserted-by":"publisher","first-page":"6338","DOI":"10.1158\/1078-0432.CCR-10-2267","volume":"17","author":"PR Blank","year":"2011","unstructured":"Blank PR, et al. KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective. Clin Cancer Res. 2011;17(19):6338\u201346.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"926_CR39","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/BF03256395","volume":"14","author":"T Shiroiwa","year":"2010","unstructured":"Shiroiwa T, Motoo Y, Tsutani K. Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer. Mol Diagn Ther. 2010;14(6):375\u201384.","journal-title":"Mol Diagn Ther"},{"issue":"S4","key":"926_CR40","doi-asserted-by":"publisher","first-page":"IV68","DOI":"10.1093\/annonc\/mdv233.230","volume":"26","author":"D Niedersuess-Beke","year":"2015","unstructured":"Niedersuess-Beke D, Schiffinger M, Mader R. Economic impact of biomarker-based anti EGFR therapies in metastatic colorectal cancer in Austria. Ann Oncol. 2015;26(S4):IV68.","journal-title":"Ann Oncol"},{"issue":"27","key":"926_CR41","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003762","volume":"95","author":"J Zhou","year":"2016","unstructured":"Zhou J, et al. Economic evaluation study (CHEER-compliant): cost-effectiveness analysis of RAS screening for treatment of metastatic colorectal cancer based on the CALGB 80405 trial. Medicine (Baltimore). 2016;95(27): e3762.","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"926_CR42","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s40258-018-0395-5","volume":"16","author":"G Harty","year":"2018","unstructured":"Harty G, Jarrett J, Jofre-Bonet M. Consequences of biomarker analysis on the cost-effectiveness of cetuximab in combination with FOLFIRI as a first-line treatment of metastatic colorectal cancer: personalised medicine at work. Appl Health Econ Health Policy. 2018;16(4):515\u201325.","journal-title":"Appl Health Econ Health Policy"},{"issue":"1","key":"926_CR43","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/COC.0000000000000231","volume":"41","author":"V Shankaran","year":"2018","unstructured":"Shankaran V, et al. Cost-effectiveness of cetuximab as first-line treatment for metastatic colorectal cancer in the United States. Am J Clin Oncol. 2018;41(1):65\u201372.","journal-title":"Am J Clin Oncol"},{"key":"926_CR44","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jcpo.2017.03.008","volume":"12","author":"S Saito","year":"2017","unstructured":"Saito S, et al. Cost-effectiveness analysis of the use of comprehensive molecular profiling before initiating monoclonal antibody therapy against metastatic colorectal cancer in Japan. J Cancer Policy. 2017;12:61\u20136.","journal-title":"J Cancer Policy"},{"issue":"7","key":"926_CR45","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.jval.2020.12.022","volume":"24","author":"T Ward","year":"2021","unstructured":"Ward T, et al. Accounting for heterogeneity in resource allocation decisions: methods and practice in UK cancer technology appraisals. Value Health. 2021;24(7):995\u20131008.","journal-title":"Value Health"},{"issue":"2","key":"926_CR46","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s40273-021-01108-4","volume":"40","author":"GE Shields","year":"2022","unstructured":"Shields GE, et al. Factors limiting subgroup analysis in cost-effectiveness analysis and a call for transparency. Pharmacoeconomics. 2022;40(2):149\u201356.","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"926_CR47","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1155\/2009\/620518","volume":"23","author":"CM Cremin","year":"2009","unstructured":"Cremin CM, et al. The identification of lynch syndrome in British Columbia. Can J Gastroenterol. 2009;23(11):761\u20137.","journal-title":"Can J Gastroenterol"},{"key":"926_CR48","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.critrevonc.2019.09.001","volume":"143","author":"K Khan","year":"2019","unstructured":"Khan K, et al. Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeniety and convergent evolution. Crit Rev Oncol Hematol. 2019;143:153\u201363.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"926_CR49","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1186\/s12885-021-08725-4","volume":"21","author":"MK Seo","year":"2021","unstructured":"Seo MK, Cairns J. How are we evaluating the cost-effectiveness of companion biomarkers for targeted cancer therapies? A systematic review. BMC Cancer. 2021;21(1):980.","journal-title":"BMC Cancer"},{"issue":"8","key":"926_CR50","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1177\/0272989X17702379","volume":"37","author":"DD Kim","year":"2017","unstructured":"Kim DD, Basu A. New metrics for economic evaluation in the presence of heterogeneity: focusing on evaluating policy alternatives rather than treatment alternatives. Med Decis Making. 2017;37(8):930\u201341.","journal-title":"Med Decis Making"},{"issue":"1","key":"926_CR51","first-page":"1","volume":"6","author":"RE Pataky","year":"2021","unstructured":"Pataky RE, et al. Real-world cost-effectiveness of bevacizumab with first-line combination chemotherapy in patients with metastatic colorectal cancer: population-based retrospective cohort studies in three Canadian provinces. MDM Policy Pract. 2021;6(1):1\u201315.","journal-title":"MDM Policy Pract"},{"issue":"4","key":"926_CR52","doi-asserted-by":"publisher","first-page":"E668","DOI":"10.9778\/cmajo.20160047","volume":"4","author":"J Telford","year":"2016","unstructured":"Telford J, et al. Performance of a quantitative fecal immunochemical test in a colorectal cancer screening pilot program: a prospective cohort study. CMAJ Open. 2016;4(4):E668\u201373.","journal-title":"CMAJ Open"},{"key":"926_CR53","unstructured":"Canadian Institute for Health Information. Patient-reported outcome measures (PROMs). 2020 June 3, 2020; Available from: https:\/\/www.cihi.ca\/proms."},{"issue":"4","key":"926_CR54","doi-asserted-by":"publisher","first-page":"8","DOI":"10.12927\/hcpap.2012.22697","volume":"11","author":"K McGrail","year":"2011","unstructured":"McGrail K, Bryan S, Davis J. Let\u2019s all go to the PROM: the case for routine patient-reported outcome measurement in Canadian healthcare. Healthc Pap. 2011;11(4):8\u201318 (discussion 55-8).","journal-title":"Healthc Pap"}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-024-00926-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40258-024-00926-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-024-00926-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T14:03:20Z","timestamp":1746453800000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40258-024-00926-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,9]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["926"],"URL":"https:\/\/doi.org\/10.1007\/s40258-024-00926-9","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,9]]},"assertion":[{"value":"22 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"REP was supported by a Canadian Institutes of Health Research Doctoral Research Award. The Canadian Network for Learning Healthcare Systems and Cost-effective \u2018Omics Innovation (CLEO) is supported by Genome BC\/Genome Canada [G05CHS]. The funders were not involved in the writing of the manuscript or the decision to submit it for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"DAR\u2019s institution has received research funding for a project from Roche Canada and DAR has received travel funding from Illumina. REP, MS, SB and SP declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of Interests"}},{"value":"REP and DAR conceptualized the study. REP acquired data and conducted data analysis, with review and verification by DAR. All authors contributed to review and interpretation of results. REP wrote the initial draft, and all authors conducted critical review and revision of the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}},{"value":"Access to data provided by the Data Stewards is subject to approval but can be requested for research projects through the Data Stewards or their designated service providers. The following data sets were used in this study: BC Cancer Registry, Population Data BC Consolidation File (Registration and Premium Billing), Hospital Separations (Discharge Abstracts Database), Medical Services Plan (MSP) Payment Information File, Vital Statistics Deaths File, and PharmaNet. You can find further information regarding these data sets by visiting the PopData project webpage at: . All inferences, opinions, and conclusions drawn in this publication are those of the author(s) and do not reflect the opinions or policies of the Data Steward(s).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Access"}},{"value":"This study was approved by the University of British Columbia-BC Cancer Research Ethics Board, certificate H15-03418.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication from Patients\/Participants"}},{"value":"Code is available by request from the corresponding author.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}